A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis.

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Peginterferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors Biogen

    • Most Recent Events

    • 28 Oct 2017 Results of a sub-group (newly diagnosed, treatment-naive patients) analysis evaluating the effect of peginterferon beta-1a on clinical and radiological disease activity presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Apr 2017 Results comparing the efficacy of subcutaneous (SC) peginterferon beta-1a and oral teriflunomide in patients from four randomised trials (ADVANCE, ATTAIN, TEMSO and TOWER), presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results comparing the effectiveness of subcutaneous peginterferon beta-1a and intramuscular interferon (IFN) beta-1a in patients from two randomised trials (ADVANCE and DECIDE), presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top